Trial Profile
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Milvexian (Primary)
- Indications Thrombosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 30 Jul 2022 Results assessing the PK, safety, and tolerability of a single oral 60 mg dose of milvexian in participants with normal renal function published in the Clinical Pharmacokinetics
- 17 May 2021 Results assessing the pharmacokinetics, safety, and tolerability of milvexian in participants with normal renal function and participants with moderate or severe renal impairment, presented at the 70th Annual Scientific Session of the American College of Cardiology.
- 13 Mar 2018 Status changed from recruiting to completed.